title: [Diagnostic imaging of treatment in osteoporosis: SERM].
abstract: The effectiveness of selective estrogen receptor modulator (SERM) in X-ray, dual X-ray Absorptiometry (DXA), quantitative computed tomography (QCT), and hip structure analysis (HSA) are reviewed. Raloxifene and bazedoxifene increase bone mineral density in the spine and femoral neck, and reduce risk of vertebral fracture in women with osteoporosis, and reduce risk of nonvertebral fractures in women with higher fracture risk. Raloxifene improved bone density and micro architecture in spine and limbs (distal radius and distal tibia) represented by volumetric QCT and high-resolution peripheral QCT. Raloxifene also improved HSA parameters in femoral neck, intertrochanter, and shaft regions. The tendency to change in these parameters is approximately similar in raloxifene and bisphosphonates (alendronate, risedronate, minodronate). These results indicate that raloxifene improved the bone density and bone quality in spine, limbs and hip.
authors: Kitago Orthopaedic Clinic/Department of Orthopaedic Surgery, Sapporo Medical University.
authors: Junichi
authors: J
authors: Takada
authors: Kousuke
authors: K
authors: Iba
authors: Toshihiko
authors: T
authors: Yamashita
mesh_terms: D015502:Absorptiometry, Photon / Q000379:methods*; D015519:Bone Density; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D005260:Female; D006620:Hip Fractures / Q000517:prevention & control; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D010024:Osteoporosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000378:metabolism; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D012306:Risk; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000517:prevention & control; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D007211:Indoles; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; C447119:bazedoxifene